A previous report involving knock-in mouse models of AML had demonstrated that, compared to mice with AML harboring mutant NPM1cA and FLT3-ITD, double mutant NPM1cA and NRAS-G12D model developed AML with a longer latency and exhibited better prognosis [48]. This evidence concerns the gene NRAS and acute myeloid leukemia.